290 related articles for article (PubMed ID: 21865087)
21. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
22. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
24. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies.
Kreimer AR; Herrero R; Sampson JN; Porras C; Lowy DR; Schiller JT; Schiffman M; Rodriguez AC; Chanock S; Jimenez S; Schussler J; Gail MH; Safaeian M; Kemp TJ; Cortes B; Pinto LA; Hildesheim A; Gonzalez P;
Vaccine; 2018 Aug; 36(32 Pt A):4774-4782. PubMed ID: 29366703
[TBL] [Abstract][Full Text] [Related]
25. Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica.
Gonzalez P; Hildesheim A; Herrero R; Katki H; Wacholder S; Porras C; Safaeian M; Jimenez S; Darragh TM; Cortes B; Befano B; Schiffman M; Carvajal L; Palefsky J; Schiller J; Ocampo R; Schussler J; Lowy D; Guillen D; Stoler MH; Quint W; Morales J; Avila C; Rodriguez AC; Kreimer AR;
Vaccine; 2015 Apr; 33(18):2141-51. PubMed ID: 25796338
[TBL] [Abstract][Full Text] [Related]
26. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.
Zhao S; Hu S; Xu X; Zhang X; Pan Q; Chen F; Zhao F
BMC Infect Dis; 2020 Nov; 20(1):846. PubMed ID: 33198657
[TBL] [Abstract][Full Text] [Related]
27. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
28. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study.
Tota JE; Struyf F; Hildesheim A; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Lehtinen M; Wheeler CM; Sampson JN
J Infect Dis; 2021 May; 223(9):1576-1581. PubMed ID: 32887990
[TBL] [Abstract][Full Text] [Related]
30. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
Szarewski A
Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
[TBL] [Abstract][Full Text] [Related]
31. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).
McKeage K; Romanowski B
BioDrugs; 2011 Aug; 25(4):265-9. PubMed ID: 21815703
[TBL] [Abstract][Full Text] [Related]
32. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.
Herrero R; Quint W; Hildesheim A; Gonzalez P; Struijk L; Katki HA; Porras C; Schiffman M; Rodriguez AC; Solomon D; Jimenez S; Schiller JT; Lowy DR; van Doorn LJ; Wacholder S; Kreimer AR;
PLoS One; 2013; 8(7):e68329. PubMed ID: 23873171
[TBL] [Abstract][Full Text] [Related]
33. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine.
Di Mario S; Basevi V; Borsari S; Balduzzi S; Magrini N
Lancet Oncol; 2012 Feb; 13(2):e50; author reply e50. PubMed ID: 22300857
[No Abstract] [Full Text] [Related]
34. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.
Szarewski A; Poppe WA; Skinner SR; Wheeler CM; Paavonen J; Naud P; Salmeron J; Chow SN; Apter D; Kitchener H; Castellsagué X; Teixeira JC; Hedrick J; Jaisamrarn U; Limson G; Garland S; Romanowski B; Aoki FY; Schwarz TF; Bosch FX; Harper DM; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Int J Cancer; 2012 Jul; 131(1):106-16. PubMed ID: 21858807
[TBL] [Abstract][Full Text] [Related]
35. Success of HPV vaccination is now a matter of coverage.
Schiffman M; Wacholder S
Lancet Oncol; 2012 Jan; 13(1):10-2. PubMed ID: 22075169
[No Abstract] [Full Text] [Related]
36. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.
Hildesheim A; Wacholder S; Catteau G; Struyf F; Dubin G; Herrero R;
Vaccine; 2014 Sep; 32(39):5087-97. PubMed ID: 25018097
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
[TBL] [Abstract][Full Text] [Related]
38. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.
Herrero R; Hildesheim A; Rodríguez AC; Wacholder S; Bratti C; Solomon D; González P; Porras C; Jiménez S; Guillen D; Morales J; Alfaro M; Cyr J; Morrisey K; Estrada Y; Cortés B; Morera LA; Freer E; Schussler J; Schiller J; Lowy D; Schiffman M;
Vaccine; 2008 Sep; 26(37):4795-808. PubMed ID: 18640170
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
[TBL] [Abstract][Full Text] [Related]
40. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
